(Q42792005)

7 November 2017

title

VRSA-doomsday superbug or damp squib? (English)

1 reference

7 November 2017

Ian M Gould

1

1 reference

7 November 2017

publication date

1 December 2010

1 reference

Lancet Infectious Diseases

7 November 2017

published in

1 reference

7 November 2017

volume

10

1 reference

7 November 2017

issue

12

1 reference

7 November 2017

page(s)

816-818

1 reference

Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970259-0

7 January 2021

10.1016/S1473-3099(10)70259-0

Identifiers

DOI

1 reference

7 November 2017

1 reference